BPC-157
ALSO SOLD AS Body Protection Compound
Last reviewed 2026-10-30
Our read Opinion
FDA now places BPC-157 in its withdrawn-nomination table, not the active Category 2 table; this is not compounding authorization. WADA 2026 S0 prohibits BPC-157.
- Type
- Research-only / unapproved
- Regulatory status
- Not FDA-approved; no verified marketing authorization
- Compounding status
- Off Category 2, review pending
- FDA-approved indications
- None
- Evidence level
- Animal studies mostly
- Routes studied
- Injection, Oral
- WADA
- Prohibited
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to support tendon, gut and tissue repair
Synthetic pentadecapeptide studied for tissue repair, angiogenesis and nitric-oxide signaling. Proposed mechanisms largely derive from animal and cell experiments.
No FDA approval. FDA identifies limited safety information and potential immunogenicity and impurity risks; marketing authorization elsewhere was not verified.
Statuses change; check the linked primary source.
Momentum Opinion
Rising
3 news items in last 30 days
Promising animal findings are not proof of injury recovery in people. Routine clinical claims substantially exceed the human evidence.
FDA.gov
The agency posted a revised list of bulk drug substances and their compounding categories.
Journal preprint
Authors identify few controlled human studies among largely preclinical literature.
WADA
Testing bodies note an increase in adverse findings involving unapproved peptides.
Skin quality, collagen, hair, and faster healing after procedures.
Gut lining repair and calmer inflammation for IBS/IBD-type symptoms and 'leaky gut'.
Whole-body repair: injury healing plus gut lining support, skin and hair quality, and lower inflammation.
Faster recovery from tendon, ligament, muscle and joint injuries; less inflammation; quicker return to training.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.